The EDC-MASLD Policy Forum, organized by the EDC-MASLD project, was held on November 19, 2024, from 10:00 to 12:00 CET in an online format. The forum aimed to bridge the gap between scientific research and regulatory needs concerning the causal links between endocrine-disrupting chemical (EDC) exposure and health outcomes, with a particular focus on metabolic-associated steatotic liver disease (MASLD). The event targeted researchers, public authorities, and EU risk assessment bodies, promoting the exchange of knowledge and the development of strategies to improve EDC risk assessment, management, and communication.
Updates from other ENKORE cluster projects were presented by experts from each project. For MERLON, Marie Louise Holmer from DTU explored ways forward for non-animal methodologies (NAMs) for identifying EDCs. For NEMESIS, Prof. Joan Grimalt from CSIC, offered insights on EDCs exposure assessment and biomarkers.
Eva Serrano Candelas, from the HYPIEND partner ProtoQSAR, presented the prospective methodologies for identifying EDCs co-exposure patterns and for assessing their effects in the development and function of the Hypothalamus-Pituitary axis.
For EDC-MASLD, You Song from NIVA, presented the utility of Adverse Outcome Pathways (AOPs) in EDCs identification and assessment. Additionally, experts from the EDC-MASLD project presented the latest evidence on the impact of EDC exposure on health outcomes.
